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Alzheimer’s disease (AD) is the most common cause of dementia and is likely caused by
defective amyloid precursor protein (APP) trafficking and processing in neurons leading to
amyloid plaques containing the amyloid-β (Aβ) APP peptide byproducts. Understanding
how APP is targeted to selected destinations inside neurons and identifying the
mechanisms responsible for the generation of Aβ are thus the keys for the advancement
of new therapies. We previously developed a mouse model with a mutation at tyrosine
(Tyr) 682 in the C-terminus of APP. This residue is needed for APP to bind to the coating
protein Clathrin and to the Clathrin adaptor protein AP2 as well as for the correct APP
trafficking and sorting in neurons. By extending these findings to humans, we found that
APP binding to Clathrin is decreased in neural stem cells from AD sufferers. Increased
APP Tyr phosphorylation alters APP trafficking in AD neurons and it is associated to
Fyn Tyr kinase activation. We show that compounds affecting Tyr kinase activity and
counteracting defects in AD neurons can control APP location and compartmentalization.
APP Tyr phosphorylation is thus a potential therapeutic target for AD.
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INTRODUCTION
Amyloid precursor protein (APP) is a ubiquitous membrane protein that plays a key role in the
development and function of neurons (Zheng and Koo, 2011; Müller and Zheng, 2012; Klevanski
et al., 2015). APP is synthesized in the endoplasmic reticulum (ER) and trafficked to the trans-
Golgi network (TGN) where it undergoes posttranslational modifications such as glycosylation
and phosphorylation to generate the APP mature form. From TGN, APP is delivered to the plasma
membrane (PM) where it can be either internalized within Clathrin-coated vesicles and transported
to the early endosome (EE, endocytic pathway) or cleaved to produce soluble APP peptides (Jiang
et al., 2014).
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Amyloid-β (Aβ peptides, which are produced via sequential
cleavage of APP by two proteases—β–secretase and γ–secretase—
are the major protein component of the amyloid plaques
observed in the brains of patients with Alzheimer’s disease (AD).
The amyloidogenic APP processing typically occurs in the acidic
cellular compartments such as late endosome (LE) and lysosome
(LYS) (Zhang et al., 2011). Alternatively, APP can undergo a
non-amyloidogenic cleavage within the Aβ sequence, which is
sequentially carried out by α–secretase and γ–secretase, thereby
precluding the formation of Aβ. Such cleavage occurs during
the APP presence on the PM (Zhang et al., 2011). Indeed,
the competition between these alternative proteolytic pathways
is crucial to the etiology of AD and is closely dependent on
the mechanism of APP endocytosis and recycling (Treusch
et al., 2011). Thus, the further identification of the factors that
mediate APP endocytosis and transport in neurons is critical for
the control and prevention of Aβ production and consequent
disease.
Alterations in Tyrosine (Tyr) phosphorylation have been
previously described in AD mice models (Georgakopoulos et al.,
2011; Yang et al., 2012). Neuritic plaques and dystrophic neurites
in AD brains contain a large amount of phosphotyrosine (pTyr)
(Masliah et al., 1991; Shapiro et al., 1991), and cultured cells
exposed to Aβ show higher levels of pTyr proteins (Bamberger
et al., 2003; Grace and Busciglio, 2003; Matrone et al., 2009).
Additionally an abnormally enhanced APP phosphorylation on
Tyr residues has been previously reported in AD brain (Russo
et al., 2001; Rebelo et al., 2007).
Tyr 682 (Tyr682) phosphorylation and dephosphorylation on
the 682YENPTY687 C-terminal domain of APP is important for
its correct uptake by endocytosis (Müller and Zheng, 2012).
Tyr682 appears to act as a switch that activates and deactivates
certain APP signaling pathways by its binding to numerous
cytosolic adaptor proteins (Matrone, 2013).
We have generated and characterized a genetically modified
mouse model with premature aging and dementia due to
a mutation of the Tyr682 residue (Y682G mutation) in APP
(Barbagallo et al., 2010). The Tyr682 mutation leads to anomalous
compartmentalization of APP, and to autophagic and neuronal
deficits (Matrone et al., 2011; La Rosa et al., 2015). Notably, mice
with the Tyr682 mutation develop progressive age-dependent
cognitive and locomotor dysfunctions, accompanied by loss
of synaptic connections, decreased neurotrophic support, and
degeneration of cholinergic neurons (Matrone et al., 2012).
Additionally, comparative pull-down experiments followed by
quantitative mass spectrometry (LC-MS/MS) analysis of mutant
(Y682G) and control mice identified the Clathrin heavy chain
as one protein among a number of others that fails to
bind to the mutated 682YENPTY687 domain (Poulsen et al.,
2015).
Although several authors have studied APP trafficking in
neurons many aspects remain unclear. In particular, little is
known of the in vivo significance of the 682YENPTY687 motif
in APP trafficking. Furthermore, the involvement of the APP
682YENPTY687 motif and its phosphorylation state in APP
trafficking on molecular recognition of adaptors remain poor
investigated.
Clathrin-mediated endocytosis is an indispensable step for
controlling APP trafficking and Aβ production (Schubert
et al., 2012; Kelly et al., 2014). Clathrin does not directly
bind membrane proteins, but does so rather through specific
adaptor proteins (AP), such as AP1-4, located in different
cell compartments and thereby controls APP trafficking and
location in neurons (King and Scott Turner, 2004; Owen et al.,
2004). In particular, AP2 mediates fast endocytosis of target
proteins, and proteins containing Tyr motifs (YxxØ motif)
have been shown to strengthen the binding to AP2 (Haucke
and De Camilli, 1999). Clathrin-mediated endocytosis is tightly
controlled, requiring the participation of AP2, dynamin I,
and a number of other factors (Sorkin, 2004). The expression
levels of several Clathrin-regulatory proteins and of genes with
known functions in Clathrin-mediated endocytosis are altered
in patients with AD (Wu et al., 2010; Thomas et al., 2011) and
at least three proteins linked to the Clathrin pathway have been
associated with AD: PICALM, BIN1, and CD2AP (Chen et al.,
2012; Parikh et al., 2014). Alterations in the Clathrin endocytic
complex have also been reported in Parkinson’s disease models
of neurodegeneration (Matrone et al., 2016).
In the present study, we investigated whether the
phosphorylation of Tyr residues of APP influences APP
trafficking and sorting in neurons from differentiated neural
stem cells (NSCs) of AD patients carrying three different
mutations in the presenilin 1 (PS1) gene (L286V; A246E;
M146L). To further support our studies, we also investigated
cortical tissues and fibroblasts from transgenic Göttingen
minipigs expressing the human PS1 mutation M146I (PS1
M146I) (Jakobsen et al., 2016).
Our results indicate that Tyr phosphorylation causes APP
mis-trafficking in diseased neurons and suggest that modulation
of Tyr682 phosphorylation could provide new therapies for AD.
METHODS
Human Neural Progenitors
Neural Stem Cells (NSCs) were purchased from Axol Bioscience
(UK). Information about the donors is readily available online
(https://www.axolbio.com/). Axol Bioscience performed the
analysis of the karyotype before and after differentiation, without
detecting any chromosome abnormality. We only maintained
neural stem cells in culture for a maximum of 6 weeks, and no
change in karyotype was expected. Protocols and details of all
reagents used for cell differentiation and culturing are available
on the Axol Bioscience webpage.
The less toxic and most active concentration of the Tyr kinase
inhibitor, Sunitinib malate (Sutent, Abcam, UK; ab141998)
was applied to control NSCs, C18, following the indications
previously reported (Son et al., 2012; Wrasidlo et al., 2014). NSCs
and fibroblasts were incubated with Sunitinib (50 µM) for 12 h.
The concentration and time of incubation (1 µM for 12 h)
of Tyr kinase inhibitor, PP2 (P0042 from Sigma, DK), were
established following a previously described protocol (Matrone
et al., 2009). Lack of toxicity was assessed by counting the number
of DAPI positive nuclei after 12 h of exposure to both Sunitinib
and PP2 (Table 2).
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The two Tyr phosphatase inhibitors, BVT948 (#B6060) and
TC2153 (#SML1299), were purchased from Sigma Aldrich (DK)
and utilized according to previously published protocols (Xu
et al., 2014). BVT948 is a non-competitive inhibitor of protein
Tyr phosphatase. TC-2153 is a potent inhibitor of STEP (STriatal-
Enriched protein tyrosine Phosphatase). Neurons were exposed
to TC2153 (TC, 1 µM) or BVT948 (BVT, 0.5 µM) for 1 h and
subsequently incubated for 2 h in fresh media without inhibitors.
Cells were then collected and processed for immunofluorescence
or Western Blotting (WB). Longer times of exposure of TC2153
and BVT948 resulted in an extensive neuronal toxicity and
death—assessed as number of DAPI positive nuclei (Table 2).
Göttingen Minipigs Carrying PS1 M146I
Mutation and Background Matched
Controls
The Göttingen minipigs were housed and handled according to
Danish law on genetically modified animals and the experiments
were conducted according to the Danish Animal Experiments
Inspectorate (license no. 2006-561/1156 and 2009-561/1733).
Fibroblasts from ear biopsies of three wild type (WT) and
three PS1 M146I minipigs were grown in DMEM with 15% fetal
bovine serum, 1% penicillin/streptomycin, 1% glutamine, and
0.01% bFGF to 90% confluence in 75 cm2 flasks.
Cortical tissues were collected from six WT and six PS1M146I
male minipigs aged between 8 and 10 months.
Western Blotting
Equal amount (30 µg) of proteins from NSCs or minipig
tissues were separated onto 4–12% Bis-Tris SDS-PAGE gels
(Invitrogen, DK or Novex system, Life Technologies), blotted
onto nitrocellulose membranes (Amersham, DK), and incubated
overnight with the appropriate primary antibody (see below).
Visualization of protein bands was performed on a Chemidoc
MP imaging system using Image Lab software (Biorad, DK).
Monoclonal anti-β-actin (A1978, Sigma Aldrich, DK) and
monoclonal anti-ß-actin-peroxidase (A3854, Sigma Aldrich, DK)
antibodies were used to normalize for protein loading.
Immunoprecipitation
For the Clathrin and AP2 immunoprecipitation (IP) assays,
protein samples were added to Dynabeads-Protein G (30 µg/100
µL) according to the manufacturer protocol (Invitrogen, DK).
The following were used for both WB and IP analysis:
rabbit monoclonal (Y188) antibody to APP (ab32136, Abcam,
UK), mouse anti-alpha adaptin antibody (AP6) specific against
AP2 (MA1-064, Thermo Fisher, DK), mouse anti-Clathrin
heavy chain antibody (clone X22) (MA1-065, Thermo Fisher,
DK). Rabbit, anti-AP1+2 antibody (ab21981) were provided by
Abcam.
APP pTyr residues were immunoprecipitated using anti-
pTyr antibody clone 4G10 R© agarose conjugate (clone 16-10,
Millipore) and analyzed with rabbit anti-APP (clone Y188)
following the same procedures previously reported (Matrone
et al., 2011). Rabbit anti-pan Fyn (#4023) and anti-Src pTyr416
(#2101) and anti-Src pTyr527 (#2105) were provided by Cell
Signaling Technology (BioNordika, DK).
ELISA
A total of 200,000 cells derived from neuronal progenitors were
cultured on 24-well plates in 0.3 ml medium, and the medium
was assayed simultaneously for Aβ42 and Aβ40 using ELISA.
ELISA was performed as previously described (Matrone et al.,
2008). After 4 and 6 weeks in culture, neurons were washed in 1X
PBS and exposed to fresh media for 24 h. Media collected after 24
h of incubation was finally centrifuged at 1000 rpm for 10 min to
eliminate cell debris and analyzed by ELISA. The Aβ42 and Aβ40
values of the samples were compared to those of standard curves,
which were generated from samples of known concentrations
(0.040–2.0 ng/ml) of Aβ40 or Aβ42. Following the procedure
previously reported (Matrone et al., 2008), the amount of Aβ40
or Aβ42 was expressed as pg of Aβ per µg of total protein.
Confocal Microscopy and Colocalization
Analysis
NSCs or fibroblasts were fixed for 20 min in PBS containing
4% formaldehyde, permeabilized with 0.05% Triton (5–10 min,
20◦C), and processed for double labeling with the appropriate
antibodies. Secondary antibodies coupled to Alexa dyes (488
or 594) were provided by Invitrogen (DK). The nuclei were
visualized by staining with DAPI (1 µg/ml) (Sigma, DK).
Digital images were obtained with a Zeiss LSM confocal lsm780
system using 63 × oil NA 1.3 objectives. The quantification
of the colocalization experiments was performed using Zen
2009 software. Pearson coefficient (R coefficient) was used as
colocalization coefficient.
The following were used for immunofluorescence analysis:
mouse monoclonal antibody (DE2B4) to Aβ (ab11132), rabbit
anti-APP (clone Y188, ab32136), mouse anti-EEA1 (1G11)
(ab70521), mouse anti-TGN46 (ab2809), rabbit anti-MAP2
(ab32454) (Abcam, UK). Rabbit anti-Rab7 (R4779) was provided
by Sigma Aldrich (DK). Rabbit anti-TubIII antibody (ab18207)
and anti-GAP-43 (ab16053) and DAPI (ab104139) were provided
by Abcam (UK). Rabbit polyclonal antibody to Clathrin heavy
chain (ab21679) was obtained from Abcam (UK). Mouse anti-
alpha adaptin antibody (AP6) (MA1-064) and mouse anti-
Clathrin heavy chain antibody (clone X22) (MA1-065) were
obtained from Thermo Fisher (DK).
Tissue Homogenization
Cortical tissue from WT and PS1 M146I minipigs was
homogenized in cold lysis buffer (40 mM Tris-HCl, 150 mM
KCl, 1% Igepal CA630 detergent, pH 7.4) supplemented with
complete Protease Inhibitor cocktail (Roche, DK), 2mM EDTA,
and 1 mM sodium orthovanadate (phoshatase inhibitor), using
a blender. After 1 h of incubation under rotation at 4◦C, the
homogenate was centrifuged at 16.000 × g for 20 min to remove
cell debris. The protein concentration of the supernatant was
estimated using a 2D Quant Kit (GE Healthcare, Little Chalfont,
UK).
Peptide Pull-down
The three synthetic peptides used for peptide pull-down (PPD)
experiments were the same as those utilized in a previous
study (Poulsen et al., 2015). Biotinylated peptides (10 nM) were
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incubated with 1mg of prewashed Dynabeads M280 Streptavidin
(Thermo Fisher Scientific, Waltham, MA, USA) for 3 h at 4◦C
under rotation. Beads were washed in blocking solution (40
mM Tris-HCl, 0.1% BSA, pH 7.4) followed by equilibration in
washing buffer (40 mM Tris-HCl, 150 mM KCl, 0.1% Igepal
CA630 detergent, pH 7.4). The Dynabeads-bound peptides were
incubated with 1mg hippocampal lysate for 18 h at 4◦C. and
washed four times. Finally beads were washed in a detergent free
buffer and eluted using 0.1 M glycine, pH 2.8.
Mass Spectrometry Sample Preparation
for Extracted Ion Chromatogram (XIC)
Quantification
Low pH eluates from peptide pull-down experiments were
lyophilized and suspended in 20 µL 8M urea, 0.2M Tris-
HCl, pH 8.3. Samples were then incubated 30 min in 5
mM dithiothreitol and 30 min in 15mM iodoacetamide.
Reduced and alkylated samples were diluted five times prior
to incubation with 0.5 µg trypsin (sequence grade, Sigma-
Aldrich Co, St. Louis, MO, USA) overnight at 37◦C. Digested
samples were acidified using formic acid and desalted by
micro-purification using POROS 50 R2 RP column material
(Applied Biosystems, Foster City, CA, USA) packed in gel-
loader tips. Micro-purified samples were suspended in 0.1%
formic acid and stored at −20◦C until being analyzed by LC-
MS/MS.
LC-MS/MS Analysis
Liquid chromatography–tandem mass spectrometry (LC-
MS/MS) analyses were performed as previously reported
(Poulsen et al., 2015). Data were acquired using an information-
dependent acquisition (IDA) method allowing post-acquisition
area-based XIC quantification. LC-MS/MS technical duplicates
were acquired for all peptide pull-down samples.
Data Processing
The Mascot Distiller 2.5.10 program was used for the area-based
XIC quantification using the following parameters. Searches
were performed against the Swiss-Prot and Tremble Sus scrofa
databases (2016_06) using Mascot 2.5 (Matrix Science, London,
UK). Trypsin was employed as an enzyme, allowing one
missed cleavage. Carbamidomethyl was entered as a fixed
modification, and oxidation of methionine was entered as a
variable modification. The mass tolerances of the precursor
and product ions were 10 ppm and 0.2 Da, respectively, and
the instrument setting was specified as ESI-QUAD-TOF. The
significance threshold (p) was set at 0.01, and the ion score cut-off
at 30. For quantification, the default average (MD) quantitation
protocol was selected using the average XIC from the three most
abundant peptides per protein. Matched rho was set to 0.8, XIC
threshold to 0.3, and isolated precursor threshold to 0.7 and the
peptide ion-score was set to 30. Mascot Distiller results were
parsed using MS Data Miner v. 1.3 (Dyrlund et al., 2012). The
XIC intensity of technical duplicates was averaged. Quantified
proteins showing at least a 5-fold up regulation when compared
to the negative controls [peptide containing a scrambled amino
acid sequence (SCR)] were included in the analysis. Furthermore,
only proteins quantified in all AD biological replicates and WT
biological replicates were considered for further analysis between
the AD andWT groups.
Statistical Analysis
Data are expressed as mean ± SEM. The various statistical tests
used are indicated in the figure legends. We performed statistical
analysis using GraphPad Prism (version 5.0c, USA).
RESULTS
APP Binding to Clathrin and AP2 Is
Reduced in Neural Stem Cells from AD
Patients Carrying Mutations in the PS1
Gene
We previously identified Tyr682 on the 682YENTPY687 C-
terminal domain as being essential for APP trafficking in a mouse
model of AD (Poulsen et al., 2015). To extend these results to
humans we investigated whether APP binding to Clathrin was
altered in human NSCs from AD patients with three different
point mutations in the PS1 gene: L286V, M146L, and A246E. All
three mutations have previously been identified in early onset
AD (Familiar AD, FAD; Rogaev et al., 1995). As controls for
our experiments, we used neural progenitors from one healthy
volunteer (C18) as well as umbilical cord (C16) neural stem cells.
Table 1 reports the basic characteristics of the patients and NSCs
analyzed.
We firstly analyzed whether NSCs developed an AD like
phenotype in culture. Neural progenitors were differentiated
for 3 weeks and cultured for an additional 3 weeks at which
point we assessed Aβ40 and Aβ42 levels by ELISA. Aβ42
increased between weeks 4 and 6 in AD neurons whereas
TABLE 1 | General description and code references of the neural progenitors used (Axol Bioscience, UK).
Disease Axol line
Control Ax0016 (C16) Cord blood CD34+ cells, new born, female
Ax0018 (C18) Healthy volunteer. Male 74 years
Alzheimer’s Disease Ax0112 Presenilin 1 L286V (LV) The donor (Caucasian) is clinically affected with Alzheimer’s disease. Onset was at age 38. Female
Ax0114 Presenilin 1A246E (AE) The donor (Caucasian), now deceased, was affected with Alzheimer’s disease. Onset was at age 45. Female
Ax0113 Presenilin 1 M146L (ML) The donor (Caucasian) is clinically affected with Alzheimer’s disease. Onset was at 53. Male
More information can be found at https://www.axolbio.com/shop/category/disease-alzheimers-12.
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FIGURE 1 | APP binding to Clathrin and AP2 is compromised in AD neurons. (A) ELISA analysis for secreted Aβ42 (Ab42) and Aβ40 (Ab40) levels from controls
(C18 and C16) and AD neurons carrying mutations in the PS1 gene (L286V, M146L, and A246E) after 4 and 6 weeks in culture. Aβ levels were assessed from media
after 24 h of plating. Data are expressed as pg/µg (pg/ug) of total protein. Each data point is the mean ± SEM of triplicate determinations of four independent
experiments. (B) Co-Immunoprecipitation (CoIP) analysis from controls (C18, C16) and AD neurons (LV, ML, AE). Samples were immunoprecipitated with rabbit
anti-APP (clone Y188) and analyzed with mouse anti-Clathrin (clone X22), mouse anti-AP2 (clone AP6), and rabbit anti-AP1 (left panel). The right panel shows total
levels of APP, Clathrin, AP2, and AP1 expression in the same samples. Densitometric analysis is reported below. Data from total lysate samples were normalized to
the corresponding β–actin values and expressed as % of C18. Data from IP samples were normalized to the corresponding APP input band and expressed as % of
C18. The data are representative of five independent experiments. Statistically significant differences were calculated by one-way ANOVA and Tukey’s post hoc test.
Aβ40 decreased (L286V; M146L; A246E, Figure 1A). In contrast,
while Aβ40 and Aβ42 were both measurable in control cells
(C18; C16) after 4 weeks in culture, no significant changes in
their levels occurred during the following 2 weeks in culture
(Figure 1A). As Aβ42 levels became evident after 4 weeks,
we decided to perform our experiments mostly at that time
period.
In order to evaluate whether APP binding to Clathrin and
AP2 is affected in AD neurons, equal amounts of proteins from
C18 andC16 controls andADneurons were immunoprecipitated
with anti-APP (CoIP APP) and analyzed via WB using anti-
Clathrin and anti-AP2 antibodies (Figure 1B). Interestingly, we
observed reduced APP binding to both Clathrin and AP2 in AD
neurons.
We further speculated that APP binding to AP1 might also
be altered in AD NSCs (Figure 1B). However, the results did not
reveal any significant alteration in AP1 binding to APP between
controls and mutated neurons, suggesting that this alteration
might be restricted or mostly narrowed to AP2-APP binding.
Importantly, no significant differences were observed in the
constitutive levels of APP, Clathrin, AP1, and AP2 in the total
lysate between controls and AD neurons (Figure 1B).
Next, we used confocal microscopy to assess colocalization
of APP and its potential partners in AD neurons. We found
decreases in the area of colocalization either between APP and
AP2 or APP and Clathrin in L286V and M146L neurons. AP2
colocalized less with APP in A246E AD neurons although the
Clathrin-APP interaction was normal (Figure 2), suggesting the
Frontiers in Molecular Neuroscience | www.frontiersin.org 5 March 2017 | Volume 10 | Article 59
Poulsen et al. Amyloid Precursor Protein Tyrosine Hyperphosphorylation
FIGURE 2 | The extent of Clathrin/APP and AP2/APP colocalization is reduced in NSCs from patients with AD. Confocal microscopy analysis of double
staining using rabbit anti-APP and mouse anti-AP2 (A) and mouse anti-Clathrin (B) in control (C18) and AD neurons with PS1 mutations (L286V; M146L; A246E).
Colocalization analysis is reported in (C). The (R) coefficient (Pearson’s coefficient) was used for the quantitative and comparative analyses. The extent of colocalization
was calculated in at least five separate fields per slide in 10 different slides for each NSCs. The data are expressed as mean ± SEM. Scale bars are 5 µm for APP/AP2
and 6 µm for APP/Clathrin colocalization. Scale bars in high-resolution pictures are 5 µm. Statistically significant differences were calculated by one-way ANOVA and
Tukey’s post hoc test.
influence of the individual background in mediating the events
reported above.
Increased Phosphorylation of APP Tyr
Residues Affects the Extent of APP
Colocalization with AP2 and Clathrin
Clathrin-dependent endocytosis of postsynaptic receptor
proteins is mediated primarily by phosphorylation of the YxxØ
motif within receptor molecules. Direct phosphorylation of this
motif or adjacent residues can decrease the binding to Clathrin
and thus alter the endocytosis of target proteins (Owen and
Evans, 1998).
We therefore investigated whether alterations in the extent
of APP Tyr residue phosphorylation affect APP colocalization
with Clathrin and AP2. Lysates from control and AD neurons
were immunoprecipitated with anti-pTyr antibody, and the
precipitates were analyzed by WB using anti-APP antibody. As
depicted in Figure 3A, pTyr APP was detectable in both control
and AD neurons. However, AD neurons exhibited a greater
increase (Figure 3B).
We next examined whether exposure to Tyr kinase inhibitors
could restore APP colocalization extent to AP2 and Clathrin
in neurons by looking at the extent of their colocalization
and overlap of immunostaining. As the extent of APP and
Clathrin colocalization was not altered in A246E neurons, the
effects of those compounds were only assessed in L286V and
M146L neurons, as well as in the control, C18. Firstly, we
performed confocal microscopy analysis after incubation with
Sunitinib, which is a multi-targeted receptor tyrosine kinase
(RTK) inhibitor currently used as anticancer drug and that
has been recently suggested as treatment for neurodegenerative
diseases (Son et al., 2012; Wrasidlo et al., 2014). The inhibitor
clearly increased the area of overlap between APP and both AP2
and Clathrin (Figures 3C,D) in AD neurons, without affecting
the APP colocalization extent in C18 neurons. As control for Tyr
Frontiers in Molecular Neuroscience | www.frontiersin.org 6 March 2017 | Volume 10 | Article 59
Poulsen et al. Amyloid Precursor Protein Tyrosine Hyperphosphorylation
FIGURE 3 | Tyr kinase inhibitors restore APP colocalization with Clathrin and AP2 in NSCs from patients with AD. (A) IP analysis of control and PS1
neurons that were exposed, or not exposed, to Sunitinib and PP2. Control C18 and AD samples (LV, ML, AE) were immunoprecipitated with anti-pTyr agarose
conjugated antibody (4G10) and analyzed with rabbit anti-APP (clone Y188). The image is representative of four independent experiments. Quantification is reported in
(B). Data were normalized with pTyr pulled down levels (input) and expressed as % of C18. Statistically significant differences were calculated by one-way ANOVA for
repeated measures followed by Tukey’s post hoc test for multiple comparisons. Confocal microscopy analysis of double staining using rabbit anti-APP and mouse
anti-AP2 (C) and mouse anti-Clathrin (D) in controls and in neurons carrying L286V or M146L mutation on PS1 gene following exposure to the Tyr kinase inhibitor
Sunitinib. The panels are representative of four different experiments performed in triplicate. (E) reports quantitative analysis of APP colocalization to AP2 and Clathrin
after 12 h of exposure to Sunitinib. (E) also reports colocalization analysis after PP2 exposure. The (R) coefficient (Pearson’s coefficient) was used for the quantitative
and comparative analyses. The extent of colocalization was calculated in five separate fields per slide in five different slides for each experimental point. The data are
expressed as mean ± SEM. Scale bars 6µm. High-resolution pictures scale bar is 4µm.
kinase inhibitor activity, we performed IP analysis on control and
AD neurons using anti-pTyr antibody and IP samples were next
analyzed using rabbit anti-APP. Our findings indicated that the
exposure to Sunitinib largely induced a decrease in APP pTyr
(Figures 3A,B) in AD neurons, thus supporting the hypothesis
that increased Tyr phosphorylation affects APP colocalization
with Clathrin and AP2. The same effects were also evident
under exposure to PP2, another Tyr kinase inhibitor selective for
Src family kinases that has been previously used to counteract
neuronal degeneration in vitro (Matrone et al., 2009; Figure 3E).
We further exposed C18 neurons to two different Tyr
phosphatase inhibitors, TC2153 and BVT948, in order to
more closely examine the hypothesis that increasing APP
Tyr phosphorylation inhibits the APP colocalization with
Clathrin and AP2. As depicted in Figures 4A–C, confocal
microscopy analysis indicated an evident reduction in the
extent of colocalization either between APP and AP2 or
APP and Clathrin following exposure to TC2153. Therefore,
phosphorylation does indeed inhibit APP colocalization with
the Clathrin endocytic complex (Figures 4A–C). Differently,
BVT948 resulted in a widespread neuronal toxicity in C18
neurons (Table 2) and it did not significantly influence the
APP binding (Figure 4C). As control of the two inhibitors’
phosphatase activity, IP analysis revealed consistent increase in
APP Tyr phosphorylation in control neurons under exposure
to TC2153 (Figure 4D). Surprisingly, however, TC2153 and
BVT948 (to a lesser extent) behaved quite differently in AD
neurons, where both inhibitors reduced the extent of APP Tyr
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FIGURE 4 | Tyr phosphatase inhibitors reduce APP colocalization with Clathrin and AP2 and increase phosphorylation of APP Tyr in control neurons.
Confocal microscopy analysis of double staining with rabbit anti-APP and mouse anti-AP2 (A) or mouse anti-Clathrin (B) in C18, L286V, and M146L neurons before
and after Tyr phosphatase inhibitor (TC2153) exposure. The panels are representative of five different experiments performed in duplicate. (C) Colocalization analysis
of APP to AP2 and Clathrin following incubation with TC2153 and BVT948 (BVT) inhibitors in C18 neurons and in AD neurons. The (R) coefficient (Pearson’s
coefficient) was used for the quantitative and comparative analyses. The extent of colocalization was calculated in five separate fields per slide in four different slides
for each experimental point. The data are expressed as mean ± SEM. Scale bars 6 µm and 4 µm. Statistically significant differences were calculated by one-way
ANOVA and Tukey’s post hoc test. (D,E). IP analysis of C18 (D) and AD neurons (E) before and after exposure to TC2153 and BVT948 (TC, BVT). Samples were
immunoprecipitated with anti-pTyr agarose conjugated antibody (4G10) and analyzed with rabbit anti-APP (clone Y188). Densitometric analysis is reported in (F). Data
were normalized with IgG levels and expressed as % of C18. Statistically significant differences were calculated using Student’s t-test.
phosphorylation, instead of further increasing it (Figures 4E,F)
and restored the extent of APP colocalization with AP2 and
Clathrin (Figures 4A–C).
APP Binding to Clathrin and AP2 Is
Compromised in Cortical Tissues and
Fibroblasts from PS1 Mutant Göttingen
Minipigs Carrying the M146I Mutation on
the PS1 Gene
To provide a further control for our experiments, and reduce
the possibility that the events described in NSCs could be
mostly due to individual genetic background, we performed the
same experiments in cortical tissues of 10-month-old Göttingen
minipigs carrying one copy of human PS1 cDNA with the
mutation Met146Ile (PS1 M146I minipigs) and in control
minipigs matched for age and genetic background (Jørgensen
et al., 1996; Jakobsen et al., 2016).
CoIP analysis of both cortical tissues and fibroblasts
revealed an approximately 50% decrease in the extent of APP
binding to AP2 and Clathrin in PS1 M146I minipigs when
compared to the corresponding controls (Figures 5A,C),
with no significant differences in the levels of APP, Clathrin,
or AP2 (Figure 5B). Confocal microscopy analysis of APP,
AP2, and Clathrin consistently revealed large decreases in
the area of overlap between either APP and AP2 or APP and
Clathrin (Figures 5D–F). As observed for human patients
cell lines, increases in the extent of APP colocalization
with AP2 and Clathrin were observed in minipigs PS1
M146I fibroblasts exposed to the Tyr kinase inhibitor
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TABLE 2 | Neuronal survival after exposure to Tyr phosphatase and Tyr
kinase inhibitors.
DAPI positive nuclei (C18)
Time of exposure (h) 0 1 12
TC2153 100 ± 7.7 102 ± 13.5 64 ± 4.8*
BVT948 100 ± 6.9 61 ± 7.3* 33 ± 6.8**
Sunitinib 100 ± 3.3 101 ± 7.2 97 ± 8.1
PP2 100 ± 11 74 ± 9.1 85 ± 9.9
The toxicity of the Tyr kinase and Tyr phosphatase inhibitors was assessed by counting
the number of DAPI positive nuclei (10 fields per slides. N = 5; Two tailed T-test). *P <
0.05 vs. time 0 and **P < 0.005 vs. time 0.
Sunitinib and to the Tyr phosphatase inhibitor TC2153
(Figures 5D–F).
Fyn Binds the 682YENPTY687 Domain of
APP in Cortical Tissues and Fibroblasts
from Göttingen Minipigs
In order to evaluate which kinase is able to bind the
682YENTPY687 domain and to potentially phosphorylate APP, we
performed LC-MS/MS analysis on APP C-terminal peptide pull-
down experiments using cortical tissues fromWT and PS1M146I
minipigs following a previously described protocol (Poulsen
et al., 2015). We found that only one Tyr kinase, Fyn, binds
the 682YENPTY687 peptide when the Tyr682 residue has been
phosphorylated, and that the interaction is higher in cortical
tissues from PS1 mutant minipigs (Figure 5G).
To confirm the results of the LC-MS/MS analysis, we
further performed CoIP analysis on cortical tissue samples and
fibroblasts from WT and PS1 M146I minipigs using anti-Fyn
antibody. Samples analyzed by WB using anti-APP antibody
revealed a large increase in APP binding to Fyn in PS1 M146I
tissues (Figures 5H–K).
Fyn Tyr kinase activity depends on the dynamic balance
between the level of phosphorylation at two Tyr sites, Tyr420 and
Tyr531. Tyr420 phosphorylation results in Fyn activation, whereas
Tyr531 phosphorylation leads to its inactivation (Hubbard,
1999; Nguyen et al., 2002). We performed WB analysis to
evaluate whether Fyn Tyr420 was phosphorylated in PS1 M146I
fibroblasts. We performed WB analysis using anti- Src pTyr416
antibody (used to detect Fyn pTyr420; Xu et al., 2015) and
anti-pan Fyn and we found a large increase in pTyr420
extent levels in PS1 M146I fibroblasts when compared to
controls (Figures 5J,K). Exposure to the Tyr kinase inhibitor,
Sunitinib, and to Tyr phosphatase inhibitor, TC2153, both
reduced Fyn Tyr420 phosphorylation in PS1 M146I fibroblasts
(Figures 5J,K).
Fyn Is Overactivated and Its Binding to APP
Is Increased in Neurons from AD Patients
Next, we assessed Fyn Tyr420 and Tyr531 phosphorylation levels
in healthy and AD neurons by performing WB using anti-
Src pTyr416, anti-Src pTyr527 antibodies (used to detect Fyn
pTyr420 and pTyr531 levels) and an anti-pan Fyn antibody. We
observed higher pTyr420 and lower pTyr531 phosphorylation
compared to control neurons in all the AD samples analyzed
(Figures 6A,B). As observed inminipigs, the exposure to TC2153
Tyr phosphatase inhibitor reduced Tyr420 phosphorylation
and rescued Tyr531 phosphorylation almost to the levels of
control neurons. Of note TC2153 was also able to rescue the
compromised APP interaction to Clathrin and AP2 in AD
neurons (Figure 4) assessed as extent of APP colocalization with
Clathrin and AP2.
To confirm that the extent of Src pTyr416 and Src pTyr527
phosphorylation was due to Fyn and not to other members of
the Src protein family, which Fyn belongs to Martin (2001), we
performed IP analysis using an antibody against Fyn endogenous
level in control (C18, C16) and AD neurons and we analyzed
samples using anti-Src pTyr416 and anti-Src pTyr527 antibodies.
In order to extend the number of samples and to give strength
to our hypothesis C16 was included in this experiment as
extra control. As we observed by WB in Figure 6A, IP analysis
confirmed that Fyn Tyr420 was largely phosphorylated and
Fyn Tyr531 was strongly dephosphorylated in AD neurons
when compared to healthy neurons (Figures 6C,D). Consistently
with data reported in PS1 M146I minipigs, the AD samples
also showed a slightly increase in the APP binding to Fyn
(Figures 6C,D).
APP Tyr Phosphorylation Alters APP
Compartmentalization in Human AD
Neurons
Finally we performed confocal microscopy analysis in AD
and control (C18) neurons by analyzing the distribution of
APP in the TGN, early EE and LE using the TGN46, EEA1
and Rab7 markers, respectively. We observed higher APP
immunostaining in TGN46-positive vesicles in neurons carrying
the L286V, M146L, and A146E mutations when compared
to the control, C18 (Figure 7A). AD neurons also showed
high APP immunostaining in the LE and lower levels in
the EE (Figures 7B–D). Notably, the same alterations were
also detectable in fibroblasts from three independent PS1
M146I minipigs when compared to two independent controls
(Figure 7F).
Consistent with the idea that an increased APP Tyr
phosphorylation in AD causes APP mistrafficking in neurons,
Tyr phosphatase inhibition with TC2153 of control neurons
(C18) upregulated APP levels in TGN46 and decreased APP in
EEA1 positive vesicles. Relevantly, in AD neurons TC2153 acted
differently than in control neurons and counteracted the defects
in APP compartmentalization (Figures 7 A,B,E).
DISCUSSION
The in vivo significance of the 682YENPTY687 domain in
APP trafficking and the involvement of the APP C-terminus
and its phosphorylation state in APP trafficking remain
barely investigated. The important new aspect emerging
from our studies is that APP phosphorylation on Tyr
residue(s) is increased in neurons from three AD affected
patients. This aberrant phosphorylation is associated with
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FIGURE 5 | APP/AP2 and APP/Clathrin binding analysis in cortical tissues and fibroblasts of Göttingen minipigs with a PS1 M146I mutation in the PS1
gene. (A) CoIP analysis of cortical tissues and fibroblasts from control (Ctrl) and PS1 M146I minipigs. Samples were immunoprecipitated with rabbit anti-APP and
analyzed with mouse anti-Clathrin (Clath) and mouse anti-AP2. (B) WB analysis of total lysate from controls (WT and Ctrl) and PS1 M146I minipigs. Densitometric
analysis is reported in (C). Data were normalized to the corresponding β-actin values and expressed as % of Ctrl. Data from CoIP samples were normalized to the
corresponding APP input amount and expressed as % of Ctrl. Statistically significant differences were calculated using Student’s t-test. (D,E) Confocal microscopy
analysis of double staining with rabbit anti-APP and mouse anti-AP2 (D) and mouse anti-Clathrin (E) in fibroblasts from Ctrl and PS1M146I minipigs in the presence of
TC2153 or Sunitinib. The panels are representative of five different experiments performed in duplicate in Ctrl and PS1 fibroblasts from two independent control (Ctrl
1-2) and three PS1 (PS1a-c) minipigs. Colocalization analysis is reported in (F). The (R) coefficient (Pearson’s coefficient) was used for the quantitative and
comparative analyses. The extent of colocalization was calculated in six separate fields per slide in four different slides for each cell line. Scale bars 1 µM and 5 µM in
high magnification. Statistically significant differences were calculated by one-way ANOVA and Tukey’s post hoc test. (G) APP C-terminal peptide affinity pull-down
analysis of cortical tissues from WT and PS1 minipigs. The table only reports information related to Fyn-APP interactions. The full list of adaptors has been provided as
additional information in Table 3. (H) IP analysis of cortical tissues and fibroblasts in control and PS1 M146I minipigs (PS1), exposed or not, to the TC2153 (TC).
Samples were immunoprecipitated with rabbit anti-Fyn antibody and analyzed using mouse anti-APP. Data were normalized to the corresponding total Fyn input
levels. Total lysate from the same samples processed for IP (H) were probed with Src pTyr416 (used to detect pFyn Tyr420 levels; Xu et al., 2015) pan Fyn antibodies
and β actin. Fyn pTyr420 levels were normalized to the corresponding total Fyn levels and expressed as % of control (WT and Ctrl). β-actin was used as loading control
(J). Densitometric analysis of panel (H,J) is reported in (I,K). Statistically significant differences were calculated by one-way ANOVA and Tukey’s post hoc test.
Fyn overactivation and to its increased binding to APP.
Tyr kinase inhibitors reverse all these events and restore
APP Tyr phosphorylation to the levels of control healthy
neurons.
Like AD patients, AD model minipigs with a PS1 mutation
also have an aberrant APP Tyr phosphorylation. Data from our
minipigs make it unlikely that Tyr phosphorylation of APP only
affects AD patients from specific individual backgrounds, but
rather they suggest a general role of the C-terminus of APP and
its phosphorylation in AD etiology.
Additionally, we demonstrate that the increased APP
Tyr phosphorylation disrupts APP binding and reduces the
colocalization extent to Clathrin and AP2 and causes alterations
in APP trafficking and sorting. However, the comprehension
of how the aberrant Tyr phosphorylation leads to APP
accumulation in TGN and LE and whether the lack in binding
Frontiers in Molecular Neuroscience | www.frontiersin.org 10 March 2017 | Volume 10 | Article 59
Poulsen et al. Amyloid Precursor Protein Tyrosine Hyperphosphorylation
FIGURE 6 | The Tyr kinase Fyn binds APP in AD neurons: (A) WB analysis performed on total lysate from control (C18) and AD neurons before or after TC2153
(TC) exposure. Samples were probed with Src pTyr416 and Src pTyr527 antibodies used to analyse Fyn pTyr420 and Fyn pTyr531 levels and were normalized to the
corresponding total Fyn levels and expressed as % of control. β-actin was used as loading control (B). (C) IP analysis of controls (C18 and C16) and AD neurons (LV,
ML, and AE). Samples were immunoprecipitated with rabbit anti-pan Fyn antibody and analyzed using rabbit anti-Src pTyr416 and rabbit anti- Src pTyr527 antibodies
(used to detect Fyn pTyr420 and pTyr531 levels; Xu et al., 2015) or mouse anti-APP (clone Y188). Data were normalized to the corresponding input Fyn levels, and
expressed as % of the correspondent C18 values (D). Densitometric analysis of (A,C) is reported in (B,D). Statistically significant differences were calculated by
one-way ANOVA and Tukey’s post hoc test.
to Clathrin and AP2 causes –or it is caused by– such alterations,
still deserve further investigation. Of note, APP has three
putative Tyr phosphorylation sites on the C-terminal domain
(Tyr653, Tyr682, and Tyr687; Oishi et al., 1997) and despite our
previous evidence pointing to the Tyr682 residue as the crucial
player in APP signaling (Matrone, 2013), we cannot exclude
the possibility that also other Tyr(s) on the APP sequence are
phosphorylated in AD patients. In this regard, it would be
of interest to understand whether APP trafficking in neurons
requires the synergic phosphorylation of these three Tyr or
rather each Tyr reciprocally coordinates the activity of the
others.
It has been previously reported that the phosphorylation of
Tyr687 residue on the 682YENPTY687 motif retains APP in TGN
and ER longer thus delaying the APP transport toward PM
(Rebelo et al., 2007). According to these results, the lack of APP
binding to AP2 and Clathrin that we observe in AD neurons
might be downstream to the deficiencies in APP trafficking
and to its accumulation in TGN. Notable, as the authors
used “phosphorylation-mimicking mutants fused to GFP” to
reproduce the phosphorylation or dephosphorylation of Tyr687
residue, it is still questionable whether these constructs might
affect per se APP motility, thus prolonging APP permanence
in TGN.
On the other hand, previous findings have reported alterations
in the APP trafficking in neurons carrying mutation on PS1.
PS1 can physically interact with APP, β-catenin, and Rab11, and
when PS1 is mutated, APP is preferentially retained in the TGN
(Dumanchin et al., 1999; Scheper et al., 2004) –thereby reducing
its levels in the PM– where it can be cleaved to generate Aβ
(Zhang et al., 2011). Following this evidence, the major player
of our results might be PS1 mutation that can influence APP
trafficking and cause the lack in APP binding to Clathrin and
AP2.
In parallel, there are also several indications suggesting that
Tyr phosphorylation might directly influence the APP binding to
Clathrin andAP2, thereby causing alterations in APP endocytosis
and trafficking. We previously reported that the mutation of
Tyr682 prevents the APP binding to Clathrin and AP2 and
causes severe neuronal deficiencies in mice (Matrone et al., 2012;
La Rosa et al., 2015; Poulsen et al., 2015). The 682YENPTY687
domain is known to be responsible for APP endocytosis (Perez
et al., 1999) and AP2 and Clathrin are both important for APP
internalization (Sorkin, 2004; Maldonado-Báez and Wendland,
2006). Clathrin- and AP2-mediated endocytosis depends on the
YxxØ motif within target molecules and the phosphorylation
of this motif or adjacent residues induces alterations in the
endocytic processes (Owen and Evans, 1998). According to this
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FIGURE 7 | APP immunofluorescence is increased in TGN46 and Rab7 and decreased in EEA1-positive vesicles in AD neurons. Confocal microscopy
analysis of double staining with rabbit anti-APP (clone Y188) and mouse anti-TGN46 (A) or mouse-anti EEA1 (B) or with rabbit anti-Rab7 (C) in C18 and AD neurons
(L286V and M146L). (A) and (B) also report confocal microscopy analysis in the presence of TC2153. Colocalization analysis is reported in (D) and (E). The same
analysis was conducted in fibroblasts from two independent controls (C1, C2) and three independent PS1 M146I minipigs (PS1a-c) (F). Data are expressed as % of
C18 in AD neurons and as % of Ctrl1 in fibroblasts. The (R) coefficient (Pearson’s coefficient) was used for the quantitative and comparative analyses. The extent of
colocalization was calculated in at least five separate fields per slide in seven different slides for each experimental point. The data are expressed as mean ± SEM vs.
Ctrl1. Scale bars 7 µM; high magnification 5 µM. Statistically significant differences were calculated using Student’s t-test.
evidence it is reasonable that increased Tyr phosphorylation
in AD neurons might directly affect APP endocytosis, causing
alternative mechanisms of APP internalization and altering APP
trafficking. Consistently, altered or alternative mechanisms of
APP endocytosis have been previously mentioned as responsible
for defects in APP trafficking in AD neurons (Jiang et al.,
2014). Previous studies have indicated a role for the Numb
protein in mediating APP endocytosis under stress-induced
Aβ production (Kyriazis et al., 2008). Indeed, the results of
our LS-MS/MS analysis indicate an increased Numb binding
to APP (Table 3). Furthermore, convincing emerging evidence
points toward an alternative APP trafficking pathway in AD.
Accordingly, non-Clathrin-dependent endocytosis of APP via
lipid rafts and caveolar pathways may also be involved in the
development of neuronal alterations and anomalies (Kang et al.,
2006; Sandvig et al., 2008).
Here, we also provide evidence that the Tyr kinase
Fyn binds APP at the 682YENPTY687 domain in neurons
from AD patients. Fyn is a 59 kDa protein belonging to
the Src family of non-receptor tyrosine kinases (SFKs), the
activity of which is regulated by a complex equilibrium
between Tyr phosphorylation and dephosphorylation (Martin,
2001). Shortly, phosphorylation at Tyr420 on the active loop
of Fyn and/or dephosphorylation of Tyr531 results in Fyn
activation. Conversely, dephosphorylation at Tyr420, such
as that mediated by striatal-enriched tyrosine phosphatase
61 (STEP61; Nguyen et al., 2002), and phosphorylation at
Tyr531,significantly reduces Fyn activity (Krämer-Albers and
White, 2011; Nygaard et al., 2014). Notably, it has been previously
reported that Aβ promotes Fyn phosphorylation (Nygaard
et al., 2014) and decreased Fyn expression prevents neuronal
decline in cellular and mouse models of AD (Lambert et al.,
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1998), thus underlining a potential clinical relevance of Fyn
in AD.
A physiological Fyn-mediated APP phosphorylation has been
previously described in COS cells and in neurons in which
APP and Fyn were overexpressed (Hoe et al., 2008). In this
study, authors present a model in which Fyn binds APP on
the 682YENPTY687 domain and mediates APP phosphorylation
on the Tyr682 residue. This increased APP Tyr phosphorylation
alters APP trafficking and causes a prolonged retention time of
APP at the cell surface (Hoe et al., 2008). These findings strongly
support our data and prospect the possibility that dysregulations
in Fyn activity might cause alterations in APP phosphorylation,
trafficking and processing. Consistently, here we report that Fyn
interacts with the APP and that this interaction is increased
in human AD neurons and in cortical tissues from PS1
M146I minipigs. We also show that Fyn phosphorylation on
Tyr420 residue and dephosphorylated on Tyr531 in AD neurons,
indicating that Fyn is overactivated in AD neurons. Accordingly,
the reduction in Tyr phosphorylation levels in AD neurons after
Tyr kinase inhibitor exposure (Sunitinib and PP2) resulted in
a decrease of Tyr phosphorylation of both APP and Fyn and
rescued the APP binding to Clathrin and AP2.
Interestingly, the exposure to the Tyr phosphatase inhibitor,
TC2153, a compound previously reported to activate Fyn,
by inhibiting STEP61 (Nguyen et al., 2002; Nygaard et al.,
2014), as expected, increased Fyn Tyr420 phosphorylation in
control neurons, thus activating Fyn signaling. The increased
Fyn Tyr420 phosphorylation is associated to increased APP Tyr
phosphorylation and to the lack of APP binding to Clathrin
and AP2 in control neurons, demonstrating that APP Tyr
phosphorylation is responsible for APPmistrafficking in neurons
and for the lack in binding to Clathrin and AP2.
However, the same inhibitor TC2153 acted differently in AD
neurons, where it caused the dephosphorylation of Tyr420 and
the phosphorylation of Tyr531, thus promoting Fyn inactivation.
Although our data are not enough to draw a firm conclusion,
one reason explaining why TC2153 behaves differently in control
and AD neurons might be the Tyr420 phosphorylation extent in
AD neurons. It is possible that when Tyr420 phosphorylation is
increased, TC2153 works on a different substrate, thus inducing
the phosphorylation of Tyr531 residues and consequently Tyr420
dephosphorylation and Fyn inactivity. Consistently with this
hypothesis, the same event was previously described by Xu et al.
in cell cultures exposed to high dose of TC2153 (Xu et al.,
2014).
Overall our results indicate that modulation of APP Tyr
phosphorylation may be valuable pharmacological strategies for
controlling APP trafficking and preventing neural degeneration
in AD and point to APP Tyr residue as valuable target for further
analysis.
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